BPC-157 + TB-500 Blend 10mg (5mg/5mg)

This pre-mixed lyophilized blend combines BPC-157 (5mg, MW 1,419.53 Da) and TB-500 (5mg, MW 4,963.44 Da) in a single vial, providing two structurally distinct peptides with non-overlapping primary molecular targets for use in multi-compound in vitro research protocols. Both components are co-lyophilized and freely soluble in aqueous buffers upon reconstitution.

BPC-157 component: A 15-amino acid pentadecapeptide (GEPPPGKPADDAGLV, CAS 137525-51-0) that primarily engages the VEGFR2 signaling cascade while modulating the nitric oxide synthase (NOS) pathway. It activates the Akt-eNOS axis for NO production, upregulates VEGF-a expression at both mRNA and protein levels, activates the FAK-paxillin focal adhesion complex, and enhances ERK1/2 MAPK phosphorylation with downstream transcription factor activation (c-Fos, c-Jun, Egr-1).

TB-500 component: The active fragment of Thymosin Beta-4 (CAS 77591-33-4), a 43-amino acid polypeptide that functions through actin-binding mechanisms and integrin receptor modulation. It forms a 1:1 stoichiometric complex with G-actin monomers via the LKKTET motif, buffering the G-actin/F-actin equilibrium to enable rapid cytoskeletal reorganization during cell motility. TB-500 also independently upregulates VEGF mRNA expression by 2.5-3.8-fold.

The two components address distinct but converging molecular pathways: BPC-157 acts upstream by modulating the signaling environment (NO-mediated vascular tone, VEGF-driven angiogenesis markers, FAK-paxillin-mediated ECM reorganization), while TB-500 acts at the cellular structural level by enabling cytoskeletal remodeling required for directional cell migration across multiple cell types.

Supplied as a lyophilized powder for in vitro research applications only. Not for human or veterinary use.

In Vitro Research Applications: This blend is designed for multi-compound in vitro protocols investigating the interplay between extracellular signaling modulation and intracellular cytoskeletal dynamics. Applicable assay formats include HUVEC proliferation (MTT/WST-1), Transwell and scratch wound migration assays, and Matrigel tube formation assays, enabling head-to-head comparison of individual versus combined compound effects on measured endpoints. Cell types commonly employed include HUVECs, NIH/3T3 fibroblasts, HaCaT keratinocytes, and primary endothelial cells.

Convergent Pathway Analysis: The blend enables investigation of pathway convergence at several nodes. Angiogenesis markers: BPC-157 upregulates VEGF-a expression and enhances NO-dependent signaling, while TB-500 promotes endothelial cell migration via actin-dependent motility, both quantifiable by VEGFR2 phosphorylation ELISA and NO production assays (Griess reagent or DAF-FM diacetate). MMP activity: Gelatin zymography can quantify differential MMP-2 (TB-500-associated) and MMP-9 (BPC-157-associated) activation profiles under single versus combined experimental conditions. Cell migration: BPC-157 primarily drives HUVEC-specific proliferation while TB-500 enables rapid cytoskeletal remodeling for directional migration across multiple cell types.

Molecular Characterization: Both components can be identified simultaneously by ESI-MS with distinct mass peaks at 1,419.53 Da and 4,963.44 Da. Purity of the blend is assessed by reversed-phase HPLC with dual-peak resolution. Reconstituted stability is evaluated by time-course HPLC in relevant buffer systems.

References

1. Huang T, et al. (2015) Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther, 9:2485-2499. PMID: 25995620
2. Philp D, et al. (2003) The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J, 17(14):2103-2105. PMID: 14500546
3. Goldstein AL, et al. (2005) Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med, 11(9):421-429. PMID: 16099219